SO

Shawn O'Brien

Mayne Pharma Group Limited | Chief Executive Officer, Managing Director
Mr O'Brien has more than 35 years of global pharmaceutical industry experience building enterprises. He was a founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. He was previously the Chairman and CEO of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences and Solstice Neurosciences. Mr O'Brien held multiple senior leadership roles at AstraZeneca, one of the global pharmaceutical companies. At AstraZeneca he was responsible for key brands such as FASLODEX, SYMBICORT, PULMICORT and SEROQUEL which all became billion-dollar brands.

Company and Roles

Company
Title
Tenure
Since
MYX
Mayne Pharma Group Limited
  • Chief Executive Officer
  • Managing Director
1yrs, 8mthOct 2022

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
MYX
Mayne Pharma Group Limited
24/10/2337,041N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
MYX
Mayne Pharma Group Limited
08/12/23
Issued
290,554$5.850$1,699,740Issue of securities
MYX
Mayne Pharma Group Limited
24/10/23
Buy
37,041$3.804$140,917On-market trade
MYX
Mayne Pharma Group Limited
16/03/23
Issued
364,103$3.570$1,299,847Issue of securities